Zhifei Bio advancing vaccine pipeline with key clinical trial milestones

Chongqing Zhifei Biological Products (SZSE:300122) has announced significant advancements in its vaccine development pipeline. The company's subsidiary, Beijing Zhifei Green Bamboo Pharmaceutical, is set to initiate Phase III clinical trials in Bangladesh for its bivalent dysentery conjugate vaccine, targeting Shigella flexneri and Shigella sonnei. This vaccine aims to address the significant global burden of bacterial dysentery, a disease affecting millions, especially children in developing countries.